Cover Image
市場調查報告書

骨質疏鬆症:開發中產品分析

Osteoporosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232788
出版日期 內容資訊 英文 296 Pages
訂單完成後即時交付
價格
Back to Top
骨質疏鬆症:開發中產品分析 Osteoporosis - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 296 Pages
簡介

骨質疏鬆症是由於骨量減少造成骨頭強度減弱而容易骨折的疾病。高齡、性別、體重輕、性荷爾蒙的不足或閉經、抽煙、某種藥劑造成致病風險。症狀是脊椎的破損和壓迫骨折的腰痛,身高低、姿勢前屈、容易骨折等,預防或治療方法有攝取鈣,維他命D、透過運動、治療藥等治療。

本報告提供骨質疏鬆症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

骨質疏鬆症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

骨質疏鬆症:企業開發中的治療藥

骨質疏鬆症:大學/機關研究中的治療藥

骨質疏鬆症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

骨質疏鬆症:企業開發中的產品

骨質疏鬆症:大學/機關研究中的產品

骨質疏鬆症的治療藥開發企業

  • Alethia Biotherapeutics Inc.
  • Alize Pharma SAS
  • Alkem Laboratories Ltd.
  • AlphaMab Co., Ltd
  • Amgen Inc.
  • Amura Holdings Limited
  • Arcarios BV
  • BiologicsMD, Inc.
  • Bone Medical Limited
  • Bone Therapeutics SA
  • Caladrius Biosciences, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Clonz Biotech Private Limited
  • Corium International, Inc.
  • Critical Pharmaceuticals Limited
  • 第一三共
  • ElexoPharm GmbH
  • Eli Lilly and Company
  • EndoCeutics, Inc.
  • Enteris BioPharma, Inc.
  • Enzo Biochem, Inc.
  • Gador S.A.
  • Galapagos NV
  • Glide Pharmaceutical Technologies Limited
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Haoma Medica Ltd.
  • Immunovo BV
  • 科研製藥
  • Korea Kolmar Co. Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Lotus Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Mereo Biopharma Group Limited
  • Mithra Pharmaceuticals S.A.
  • Novartis AG
  • Omeros Corporation
  • Oncobiologics, Inc.
  • Oscotec Inc.
  • Osteologix Holdings Plc.
  • Paras Biopharmaceuticals Finland Oy
  • PhytoHealth Corporation
  • R-Pharm
  • Radius Health, Inc.
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Shin Poong Pharm.Co., Ltd.
  • Sinil Pharmaceutical Co., Ltd
  • STELIS Biopharma Pvt. Ltd.
  • 大日本住友製藥
  • TAmiRNA GmbH
  • TechnoPhage SA
  • Terpenoid Therapeutics, Inc.
  • TSH Biopharm Corporation Limited
  • Uni-Bio Science Group Ltd.
  • Wroclawskie Centrum Badan EIT+ Sp. z o.o.
  • Yooyoung Pharmaceutical Co., Ltd.
  • Zosano Pharma Corporation
  • Zydus Cadila Healthcare Limited

骨質疏鬆症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

骨質疏鬆症:最近的開發平台趨勢

骨質疏鬆症:暫停中的計劃

骨質疏鬆症:開發中止的產品

骨質疏鬆症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8638IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 4, 8, 14, 1, 54 and 10 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively for Osteoporosis.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Osteoporosis Overview
  • Therapeutics Development
  • Osteoporosis - Therapeutics under Development by Companies
  • Osteoporosis - Therapeutics under Investigation by Universities/Institutes
  • Osteoporosis - Pipeline Products Glance
  • Osteoporosis - Products under Development by Companies
  • Osteoporosis - Products under Investigation by Universities/Institutes
  • Osteoporosis - Companies Involved in Therapeutics Development
  • Osteoporosis - Therapeutics Assessment
  • Drug Profiles
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Osteoporosis, H2 2016
  • Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Osteoporosis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H2 2016
  • Osteoporosis - Pipeline by Alize Pharma SAS, H2 2016
  • Osteoporosis - Pipeline by Alkem Laboratories Ltd., H2 2016
  • Osteoporosis - Pipeline by AlphaMab Co., Ltd, H2 2016
  • Osteoporosis - Pipeline by Alvogen Korea Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Amgen Inc., H2 2016
  • Osteoporosis - Pipeline by Amura Holdings Limited, H2 2016
  • Osteoporosis - Pipeline by Arcarios BV, H2 2016
  • Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016
  • Osteoporosis - Pipeline by Bone Biologics, Corp., H2 2016
  • Osteoporosis - Pipeline by Bone Therapeutics SA, H2 2016
  • Osteoporosis - Pipeline by Cellmid Limited, H2 2016
  • Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2016
  • Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Corium International, Inc., H2 2016
  • Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H2 2016
  • Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2016
  • Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016
  • Osteoporosis - Pipeline by EndoCeutics, Inc., H2 2016
  • Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016
  • Osteoporosis - Pipeline by Enzo Biochem, Inc., H2 2016
  • Osteoporosis - Pipeline by Gador S.A., H2 2016
  • Osteoporosis - Pipeline by Galapagos NV, H2 2016
  • Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
  • Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Osteoporosis - Pipeline by Haoma Medica Ltd., H2 2016
  • Osteoporosis - Pipeline by Immunovo BV, H2 2016
  • Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
  • Osteoporosis - Pipeline by Ipsen S.A., H2 2016
  • Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Osteoporosis - Pipeline by Merck & Co., Inc., H2 2016
  • Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H2 2016
  • Osteoporosis - Pipeline by Midway Pharmaceuticals, Inc., H2 2016
  • Osteoporosis - Pipeline by Mithra Pharmaceuticals S.A., H2 2016
  • Osteoporosis - Pipeline by NIBEC, H2 2016
  • Osteoporosis - Pipeline by Novartis AG, H2 2016
  • Osteoporosis - Pipeline by Omeros Corporation, H2 2016
  • Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016
  • Osteoporosis - Pipeline by Oscotec Inc., H2 2016
  • Osteoporosis - Pipeline by OsteoGeneX Inc., H2 2016
  • Osteoporosis - Pipeline by Osteologix Holdings Plc., H2 2016
  • Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
  • Osteoporosis - Pipeline by Pfenex Inc., H2 2016
  • Osteoporosis - Pipeline by PhytoHealth Corporation, H2 2016
  • Osteoporosis - Pipeline by R-Pharm, H2 2016
  • Osteoporosis - Pipeline by Recursion Pharmaceuticals, LLC, H2 2016
  • Osteoporosis - Pipeline by Ribomic Inc., H2 2016
  • Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
  • Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016
  • Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by TAmiRNA GmbH, H2 2016
  • Osteoporosis - Pipeline by TechnoPhage SA, H2 2016
  • Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H2 2016
  • Osteoporosis - Pipeline by TSH Biopharm Corporation Limited, H2 2016
  • Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H2 2016
  • Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2016
  • Osteoporosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
  • Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Osteoporosis - Dormant Projects, H2 2016
  • Osteoporosis - Dormant Projects (Contd..1), H2 2016
  • Osteoporosis - Dormant Projects (Contd..2), H2 2016
  • Osteoporosis - Dormant Projects (Contd..3), H2 2016
  • Osteoporosis - Dormant Projects (Contd..4), H2 2016
  • Osteoporosis - Dormant Projects (Contd..5), H2 2016
  • Osteoporosis - Dormant Projects (Contd..6), H2 2016
  • Osteoporosis - Dormant Projects (Contd..7), H2 2016
  • Osteoporosis - Dormant Projects (Contd..8), H2 2016
  • Osteoporosis - Dormant Projects (Contd..9), H2 2016
  • Osteoporosis - Dormant Projects (Contd..10), H2 2016
  • Osteoporosis - Dormant Projects (Contd..11), H2 2016
  • Osteoporosis - Discontinued Products, H2 2016
  • Osteoporosis - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Osteoporosis, H2 2016
  • Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top